Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
03/2013
03/28/2013CA2847797A1 Benzoic acid derivatives as eif4e inhibitors
03/28/2013CA2847540A1 Pyrrolopyrimidine and purine derivatives
03/28/2013CA2847186A1 Compounds useful as inhibitors of choline kinase
03/28/2013CA2846758A1 Triazolopyridine compounds as pde10a inhibitors
03/28/2013CA2846630A1 Combination treatments comprising c-met antagonists and b-raf antagonists
03/28/2013CA2846369A1 N-[4-(1h-pyrazolo[3,4-b]pyrazin-6-yl)-phenyl]-sulfonamides and their use as pharmaceuticals
03/28/2013CA2845890A1 Estrogen receptor ligands and methods of use thereof
03/28/2013CA2845409A1 Imidazopyridine compounds, compositions and methods of use
03/28/2013CA2845388A1 Beta-lactam compounds for enhancing t cell-mediated immune responses
03/28/2013CA2845170A1 New bicyclic dihydroquinoline-2-one derivatives
03/28/2013CA2844654A1 N-(3-(2-amino-6,6-difluoro-4,4a,5,6,7,7a-hexahydro-cyclopenta[e][1,3]oxazin-4-yl)-phenyl)-amides as bace1 inhibitors
03/28/2013CA2843211A1 New thio derivatives bearing lactams as potent hdac inhibitors and their uses as medicaments
03/28/2013CA2834327A1 New abuse-resistant pharmaceutical composition for the treatment of opioid dependence
03/28/2013CA2832309A1 8-ethyl-6-(aryl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of nervous system disorders and cancer
03/28/2013CA2823548A1 Heteroaryl compounds as 5-ht4 receptor ligands
03/27/2013EP2573176A1 Tumour growth inhibitory compounds and methods of their use
03/27/2013EP2573170A2 Adeno-associated virus (AAV) serotype 9 sequences, vectors containing same, and uses therefor
03/27/2013EP2573100A1 Total synthesis of the core tetrasaccharide of the lipopolysaccharide from Neisseria meningitidis
03/27/2013EP2573090A1 (6,7-dihydro-2-nitro-5h-imidazol[2,1-b][1,3]oxazin-6-yl) amide compounds, preparation methods and uses thereof
03/27/2013EP2573089A1 Novel artmisinin derivatives
03/27/2013EP2573088A1 Pyrano[3,2-c]benzopyran-6(2h)-one derivatives and uses thereof
03/27/2013EP2573087A1 Pyridin-2-yl-amino-1,2,4-thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus
03/27/2013EP2573086A1 N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate
03/27/2013EP2573085A1 N-[5-(aminosulfonyl)-4methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl] acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range
03/27/2013EP2573083A1 Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
03/27/2013EP2573082A1 Crystalline solvated forms of (r)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1h-benzimidazole
03/27/2013EP2573081A1 Prophylactic and/or therapeutic agent for non-alcoholic steatohepatitis
03/27/2013EP2573080A1 Isoindoline compounds for the treatment of spinal muscular atrophy and other uses
03/27/2013EP2573079A2 Benzimidazole quinolinones and uses thereof
03/27/2013EP2573078A1 Acrylamide compounds and use thereof for inhibiting apoptosis
03/27/2013EP2573073A1 Pyrazoloquinolinone derivatives, preparation thereof and therapeutic use thereof
03/27/2013EP2573072A1 Indenoquinolone compound, preparation method and use thereof
03/27/2013EP2573070A1 Crystal form of (s)-4-hydroxy-2-oxo-1-pyrrolidine acetamide, preparation method and use thereof
03/27/2013EP2573069A2 Inhibitors of histone deacetylase and prodrugs thereof
03/27/2013EP2573068A1 Process for preparing intermediates of compounds useful as opioid receptor modulators
03/27/2013EP2573067A1 Aromatic butan-2-ol compounds, preparation methods and uses thereof
03/27/2013EP2572730A1 Method for prevention or treatment of metabolic syndrome
03/27/2013EP2572721A1 Pharmaceutical composition including an hif-2 inhibitor as an active ingredient for preventing or treating arthritis
03/27/2013EP2572719A1 Use of poloxamines as inducers of the osteogenic differentiation of mesenchymal cells
03/27/2013EP2572718A1 Methods and related compositions for reduction of fat
03/27/2013EP2572717A1 Pharmaceutical composition containing solifenacin
03/27/2013EP2572716A1 Anti-inflammatory Composition
03/27/2013EP2572715A1 Immunostimulatory Combinations
03/27/2013EP2572714A1 Immunostimulatory Combinations
03/27/2013EP2572713A1 Extracts and isolated flavonoids from Euphorbia cuneata useful as anti-ulcer agents
03/27/2013EP2572712A2 Treatment of viral infections by modulation of host cell metabolic pathways
03/27/2013EP2572711A1 Antimalarial drug which contains 5-aminolevulinic acid or derivative thereof as active ingredient
03/27/2013EP2572710A2 Novel use of panduratin derivatives or an extract of boesenbergia pandurata for promoting muscle mass growth, fighting fatigue, and enhancing exercise performance capability
03/27/2013EP2572709A1 HSP90 inhibitors for therapeutic treatment
03/27/2013EP2572706A1 Lipid membrane structure with nuclear transferability
03/27/2013EP2572705A1 Orodispersible tablets
03/27/2013EP2572704A1 Orally-Disintegrating Formulations of Vildagliptin
03/27/2013EP2572703A1 Compressed oral dosage form for asenapine maleate
03/27/2013EP2572702A1 Biodegradable single-phase cohesive hydrogel
03/27/2013EP2572589A1 Pig feed, and method for feeding same
03/27/2013EP2572199A1 Combination
03/27/2013EP2571989A1 Method for reducing expression of downregulated i renal cell carcinoma i malignant gliomas
03/27/2013EP2571988A1 Compositions for use in treating or diagnosing bone disorders and/or cardiovascular disorders
03/27/2013EP2571900A1 Improved anti-serum albumin binding variants
03/27/2013EP2571885A1 Method for purifying a fused pyrrolocarbazole derivative
03/27/2013EP2571884A2 Mtor selective kinase inhibitors
03/27/2013EP2571882A1 Heterocyclic flaviviridae virus inhibitors
03/27/2013EP2571881A1 Pyrrolopyrazine derivatives as syk and jak inhibitors
03/27/2013EP2571880A1 Pyrrolo [2, 3 - b]pyrazine - 7 - carboxamide derivatives and their use as jak and syk inhibitors
03/27/2013EP2571879A1 Heterobiaryl-cyclohexyl-tetraazabenzo[e]azulenes
03/27/2013EP2571878A1 Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b]pyridine compounds as modulators of protein kinases
03/27/2013EP2571877A1 1h - imidazo [4, 5 - c]quinolines
03/27/2013EP2571875A1 Male contraceptive compositions and methods of use
03/27/2013EP2571874A1 A crystalline form of (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate
03/27/2013EP2571872A1 Compounds
03/27/2013EP2571871A1 Process for the preparation of chiral triazolones
03/27/2013EP2571870A1 Ccr2 antagonists and uses thereof
03/27/2013EP2571867A1 Novel pyrimidine derivatives
03/27/2013EP2571865A1 2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl-sulfonamide derivatives
03/27/2013EP2571864A1 Piperidinyl-substituted lactams as gpr119 modulators
03/27/2013EP2571863A1 Nilotinib salts and crystalline forms thereof
03/27/2013EP2571862A1 Prodrug of triazolone compound
03/27/2013EP2571860A1 2-phenyl benzoylamides
03/27/2013EP2571858A1 Phenylmorpholines and analogues thereof
03/27/2013EP2571856A1 Compounds
03/27/2013EP2571853A1 Inhibitors of human 12-lipoxygenase
03/27/2013EP2571847A1 Process for the preparation of chiral hydrazides
03/27/2013EP2571577A1 Improved immunotherapeutic dosing regimens and combinations thereof
03/27/2013EP2571576A2 N-(aminoacyl)-amino compound
03/27/2013EP2571575A1 Compositions for the treatment of gynaecological disorders
03/27/2013EP2571517A2 Long - acting formulations of insulins
03/27/2013EP2571515A2 Methods and assays for treating subjects with shank3 deletion, mutation or reduced expression
03/27/2013EP2571507A1 Formulations and methods of treatment of skin conditions
03/27/2013EP2571506A1 Processes for preparing macrolides and ketolides and intermediates therefor
03/27/2013EP2571505A1 Posology and administration of glucocorticoid based compositions
03/27/2013EP2571504A1 Use of aromatase inhibitors for synchronizing ovulation, inducing superovulation or double ovulation and improving twinning and fertility in a mammal
03/27/2013EP2571503A2 Compositions and methods for treating neoplasia, inflammatory disease and other disorders
03/27/2013EP2571502A1 Theobromine for increasing hdl-cholesterol
03/27/2013EP2571501A1 Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy
03/27/2013EP2571500A1 Treatment for altitudinal hypoxia
03/27/2013EP2571499A1 Pharmaceutical composition comprising n- acetylcysteine and a xanthine
03/27/2013EP2571498A1 Pharmaceutical aqueous compositions comprising lipoic acid as an antioxidant
03/27/2013EP2571497A2 Methods and compositions related to a retinoid receptor-selective pathway
03/27/2013EP2571495A1 A pharmaceutical controlled release composition of losartan
03/27/2013EP2571493A1 Preparations of biologically active substances with enlarged surface area based on amphiphilic copolymers
1 ... 780 781 782 783 784 785 786 787 788 789 790 791 792 793 794 795 796 797 798 799 800 ... 7860